Nektar Therapeutics
Nektar Therapeutics (NKTR) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
nktr · stock forecast · 33 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 33 Wall Street analysts in the past 3 months
Buy
33 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$192
Consensus
$150
+167.6% upside
Low
$80.00
Median: $151 · Last Close: $55.90
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$149.60
167.6% upside
High Target
$192
243.5%
Low Target
$80
43.1%
Current Price
$55.90
as of today
Based on analyst price targets, the NKTR stock price prediction for the next 12 months ranges from $80 to $192. The consensus NKTR price forecast of $149.60 implies 167.6% upside from the current price of $55.90.
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $53.10 | ↓ 5.00% |
1-day model range: $52.76–$53.44. Peak: $53.44 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · NKTR · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-11 | Wedbush | Maintains | Neutral→Neutral |
| 2026-05-08 | Piper Sandler | Maintains | Overweight→Overweight |
| 2026-04-21 | Citigroup | Maintains | Buy→Buy |
| 2026-04-21 | Wedbush | Maintains | Neutral→Neutral |
| 2026-04-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-04-20 | BTIG | Maintains | Buy→Buy |
| 2026-03-16 | Citigroup | Maintains | Buy→Buy |
| 2026-02-23 | B. Riley Securities | Maintains | Buy→Buy |
| 2026-02-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-02-10 | BTIG | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Nektar Therapeutics (NKTR) stock. Of the recent 110 rating actions, 9 were upgrades and 17 were downgrades. 33 analysts currently cover NKTR.
Analyst Recommendation Trends
NKTR analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$41M
↓ 21.3% YoY
Revenue Next Year
$37M
↓ 10.5% YoY
EPS This Year
$-9.06
EPS Next Year
$-11.07
↑ 22.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast NKTR EPS of $-9.06 for the current fiscal year, based on estimates from 7 analysts. The NKTR revenue forecast is $41M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The NKTR stock forecast is supported by two independent data sources: analyst consensus ratings from 33 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NKTR price target is $149.60 (+167.6% upside), with an analyst consensus of Buy.
The NKTR short-term stock prediction for tomorrow is $53.10 (-5.00%).
Nektar Therapeutics trades on NASDAQ under the ticker NKTR. The NKTR stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.
Frequently asked questions
NKTR forecast · 8 questionsAccording to 33 Wall Street analysts, the average 12-month NKTR price target is $149.60, with a high forecast of $192.00 and a low of $80.00. The median price target is shown in the chart above when available. This implies +167.6% potential upside from the current price of $55.90.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.